Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
109.84
+1.58 (1.46%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Rhythm Pharmaceuticals stock have an average target of 139.07, with a low estimate of 105 and a high estimate of 159. The average target predicts an increase of 26.61% from the current stock price of 109.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $130 | Buy | Maintains | $130 | +18.35% | Jun 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $143 → $151 | Buy | Maintains | $143 → $151 | +37.47% | Jun 16, 2026 |
| Jefferies | Jefferies | Buy Maintains $125 | Buy | Maintains | $125 | +13.80% | Jun 15, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $158 → $159 | Buy | Maintains | $158 → $159 | +44.76% | Jun 15, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $136 | Buy | Reiterates | $136 | +23.82% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
298.08M
from 189.76M
Increased by 57.08%
Revenue Next Year
539.23M
from 298.08M
Increased by 80.90%
EPS This Year
-3.26
from -3.11
EPS Next Year
-0.74
from -3.26
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 321.0M | 622.1M | |
| Avg | 298.1M | 539.2M | |
| Low | 273.6M | 435.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 69.2% | 108.7% | |
| Avg | 57.1% | 80.9% | |
| Low | 44.2% | 45.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.45 | 1.18 | |
| Avg | -3.26 | -0.74 | |
| Low | -4.02 | -2.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.